Notes from the Field: Rollout of Nirsevimab to Protect Infants and Young Children During the Respiratory Syncytial Virus Season — New York City, 2023–2024
- Melanie Askari; Kristin Oliver; Denise Benkel; Melissa Mickle-Hope; Vincent Tam; Marisa Langdon-Embry
Access Resources
About
This analysis reviewed nirsevimab dosing based on Vaccines for Children (VFC) eligibility in New York City during the 2023–24 RSV season. A nirsevimab shortage in October 2023 affected the market and VFC program. CDC recommended prioritizing high-risk infants, changing the allocation strategy. In NYC, most children get free immunizations. An assessment showed only 1/3 of birthing hospitals followed the distribution plan, with 37% VFC-eligible and 45% non-eligible infants receiving nirsevimab in the first week. Hospitals should join VFC, provide nirsevimab to eligible infants before discharge for better public health.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.